Although allogeneic bone marrow transplantation (BMT) has the potential to cure patients with paroxysmal nocturnal hemoglobinuria (PNH), experience with transplantation from matched unrelated donor (MUD) in PNH is limited to five reports describing a total number of 18 transplants with 50% survival [1] [2] [3] [4] [5] (Table 1 ). The significance of additional transplant-related risk factors for hemolysis, including potentially severe hemolysis due to Kidd group incompatibility, is unknown. Also an optimal preparative regimen in PNH has not yet been established.
We report MUD BMT for 35-year-old male PNH patient with refractory hemolysis and multiple BMTrelated risk factors for hemolysis. Severe hemolytic anaemia was diagnosed 18 months prior to transplantation. Diagnosis of PNH was confirmed by flow-cytometric detection of complement inhibitor CD55 (DAF-decay accelerating factor) and CD59 (MIRL-membrane inhibitor of reactive lysis) defect present on 95% of erythrocytes and granulocytes. The patient was initially treated for 9 months with steroids (prednisone, methylprednisolone). Iron and folic acid were initially supplied to remedy their insufficiency. Pretransplantation substitutive therapy consisted of 10 transfusions of filtered washed RBCs performed with increasing frequency. At admission prior to BMT obvious signs of severe, progressive, refractory hemolysis were present: LDH 1886 U/l, haptoglobin 0.077 g/l and following morphological values: Hb 7.8 g/dl, Er 2.2 T/l, reticulocytes 98 promille. The donor was a 10-allele HLA-matched 38-year-old male. BMT-related risk factors for hemolysis were major Kidd group incompatibility (Jk(b) antigen present in donor and anti-Jk(b) alloantibodies detectable in recipient in titer 1:2); minor AB0 incompatibility (group 0 in donor with anti-B titer 1:16, group B in recipient); Rh difference (donor positive, recipient negative). Other risk factors included seronegative CMV status in the donor and seropositive in the recipient, arterial hypertension, steroidrelated diabetes mellitus and probable former thrombotic episode (leading to nasal septum perforation). Myeloablative conditioning consisted of Treosulfan 3 Â 14 g/m 2 on days from À6 to À4, Fludarabine 5 Â 30 mg/m 2 on days from À6 to À2, Thymoglobulin total dose 4.5 mg/kg on days from À3 to À1. The rationale for use of treosulfanbased conditioning was its favorably low nonhematological toxicity profile and myeloablative efficiency demonstrated previously in a dose-finding study, 6 although it was not used before for PNH. The nonmyeloablative conditioning regimens consisting of fludarabine with either TBI 5, 7 or cyclophosphamide 8, 9 were reported to have enough potential to eliminate the PNH clone and allow engraftment.
Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin-A 3 mg/kg/d and methotrexate 15 mg/m 2 on day þ 1 and 10mg/m 2 on days þ 3, þ 6 and þ 11. Gancyclovir was administered for 19 days for prophylaxis of CMV reactivation and i.v. immunoglobulins were given. Low-molecular weight heparins -subcutaneous enoxaparin followed by i.v. nadroparin during thrombocytopenia -were used for the prophylaxis of venal thrombosis before and after the transplantation due to the history of thrombotic episode and were discontinued on day þ 31 post transplantion, after confirmation of low D-dimers level.
Transplanted bone marrow was depleted of Er using a Fenwall CS3000 Plus due to major Kidd group incompatibility to avoid hemolysis (which was not planned in advance before harvesting), and contained 0.5 Â 10 8 NC/kg, 2.1 Â 10 6 CD34 þ cells/kg and 12.5 Â 10 6 CD3 þ cells/kg. No toxicity but mild nausea related to conditioning was observed. Myeloablation was complete with 20 days of agranulocytosis o0.5 granulocytes (G)/l, including 11 days of absolute agranulocytosis o0.1 G/l. No serious complications were observed during the post transplant aplasia. Filtered washed Er 0RhÀJk(b)À were transfused 7 Â and single-donor platelets 7 Â in this period. Regeneration was Hemolysis gradually decreased (LDH o400 U/l since day þ 5, normal haptoglobin 40.7 g/l since day þ 38). Anti-Jk(b) alloantibodies titer reached 0 on day þ 31, after which they were detectable only with use of a micromethod. On day þ 70 the patient was readmitted due to CMV reactivation confirmed by the bio-molecular PCR method. Although initial treatment with ganciclovir for 2 weeks led to decrease of CMV load in both cells and serum, severe pancytopenia developed and required intensive substitutional therapy: single-donor platelets (7 Â ) and washed filtered 0RhÀJk(b)À erythrocytes (5 Â ) transfusions. Thus foscarnet was administered for 6 more weeks. Intravenous immunoglobulins were given every week during CMV treatment due to hypoimmunoglobulinaemia. Complete elimination of CMV was achieved on day þ 123, after 2 months of intensive antiviral treatment and was followed by return of regeneration in all cell lines. Full 100% donor chimerism was achieved on day þ 28 (STR, short tandem repeat) and was re-confirmed on day þ 71 (STR) and on day þ 99 (YNZ). A steady decrease in the recipient-type population of erythrocytes was observed (from 24% on day þ 30, 7% on day þ 70 and residual 1% on day þ 98). Complete eradication of the PNH clone was confirmed by absence of complement inhibitor CD55 (DAF) and CD59 (MIRL) defects on 100% of erythrocytes and granulocytes in flow-cytometric evaluation performed on day þ 160. The patient has no signs of chronic GVHD, hemolysis nor PNH, over 300 days following BMT, and has returned to work.
We conclude that MUD BMT can be offered as an effective treatment option for PNH patients. Multiple transplant-related risk factors for hemolysis can be managed without exacerbation of hemolysis during the procedure. When anti-Kidd antibodies are present in the recipient, the donor should be tested for relative Kidd antigen and in case of major Kidd group incompatibility, erythrocytes should be depleted from the donor's bone marrow before transplantation. To our knowledge major Kidd group incompatibility between donor and recipient of the bone marrow has not been described before. Treosulfan, Fludarabine and Thymoglobulin treatment can be safely and effectively used for conditioning in PNH. 
